Impact Biomedical IBO
NYSE IBO
$3.60 -0.20 (-5.26%)
As of: Oct 23, 2026 · 3:58 PM EDT

Impact Biomedical (IBO) EBIT Margin (2022 - 2026)

Updated

Impact Biomedical's EBIT Margin was -23400.00% in Q2 2026, down 6928.57 percentage points from -16471.43% a year earlier but up 9300.00 percentage points from the prior quarter.

Analysis

Impact Biomedical (IBO) EBIT Margin (2022 - 2026) Analysis & Trends

On a trailing twelve-month basis, Impact Biomedical's EBIT Margin was -14548.57% through Jun 30, 2026, up 37242.66 percentage points year-over-year; for FY2022, it came in at -6808.00%.

  • Quarterly EBIT Margin has moved between -32700.00% (Q1 2026) and -1500.00% (Q2 2022) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 24.35%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 37.86%
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn -3.52%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 20.57%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -133.21%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 28.37%
10 Impact Biomedical 384.92 Mn 384.88 Mn 2,000.00 -23,400.00%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -23,400.00%
Mar 31, 2026 -32,700.00%
Sep 30, 2025 -5,266.67%
Jun 30, 2025 -16,471.43%
Mar 31, 2025 -33,666.67%
Dec 31, 2024 -874,366.67%
Sep 30, 2024 -37,566.67%
Jun 30, 2024 -20,866.67%
Mar 31, 2024 -25,700.00%
Dec 31, 2023 -37,966.67%
Sep 30, 2023 -35,933.33%
Jun 30, 2022 -1,500.00%
API Access

Impact Biomedical EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IBO&period=max&api_key=YOUR_API_KEY